Fighting the Opioid Epidemic: Privacy concerns are hampering the effectiveness of prescription drug monitoring programs.
- Published in:
- Government Technology, 2017, v. 30, n. 4, p. 55
- By:
- Publication type:
- Article
Works matching DE "PHARMACY benefit management"
Results: 98
1
2
The Great Divide: ERISA Integrity versus State Desire to Hold Pharmacy Benefit Managers Accountable for Pharmaceutical Drug Pricing.
- Published in:
- Journal of Corporation Law, 2018, v. 44, n. 1, p. 171
- By:
- Publication type:
- Article
3
Baby Boomers' Adoption of Consumer Health Technologies: Survey on Readiness and Barriers.
- Published in:
- Journal of Medical Internet Research, 2014, v. 16, n. 9, p. 1, doi. 10.2196/jmir.3049
- By:
- Publication type:
- Article
4
Drug Pricing for Competing Pharmaceutical Manufacturers Distributing through a Common PBM.
- Published in:
- Production & Operations Management, 2018, v. 27, n. 8, p. 1399, doi. 10.1111/poms.12867
- By:
- Publication type:
- Article
5
An Over-the-Counter Contraceptive Is Approved: The Reproductive Autonomy Imperative.
- Published in:
- JGIM: Journal of General Internal Medicine, 2024, v. 39, n. 8, p. 1499, doi. 10.1007/s11606-024-08749-z
- By:
- Publication type:
- Article
6
Opioid Prescribing and Opioid Risk Mitigation Strategies in the Veterans Health Administration.
- Published in:
- JGIM: Journal of General Internal Medicine, 2020, v. 35, n. 3, p. 927, doi. 10.1007/s11606-020-06258-3
- By:
- Publication type:
- Article
7
Opioid Prescribing and Opioid Risk Mitigation Strategies in the Veterans Health Administration.
- Published in:
- 2020
- By:
- Publication type:
- journal article
8
Predicting pharmaceutical supply chain disruptions before and during the COVID‐19 pandemic.
- Published in:
- Risk Analysis: An International Journal, 2024, v. 44, n. 12, p. 2797, doi. 10.1111/risa.17453
- By:
- Publication type:
- Article
9
PRESIDENT'S perspective.
- Published in:
- Michigan Medicine, 2018, v. 117, n. 3, p. 4
- By:
- Publication type:
- Article
10
A PRESCRIPTION FOR CALAMITY: WHY THE DEPARTMENT OF LABOR'S PHARMACY BENEFIT MANAGEMENT PROGRAM FALLS SHORT AS A SINGULAR SOLUTION TO THE U.S. OPIOID CRISIS.
- Published in:
- Public Contract Law Journal, 2023, v. 52, n. 2, p. 277
- By:
- Publication type:
- Article
11
The Journal of Generic Medicines – Editorial March 2025.
- Published in:
- 2025
- By:
- Publication type:
- Editorial
12
Demand Inertia and the Hidden Impact of Pharmacy Benefit Managers.
- Published in:
- Management Science, 2024, v. 70, n. 12, p. 8940, doi. 10.1287/mnsc.2021.03331
- By:
- Publication type:
- Article
13
Impact of the Inflation Reduction Act on Patient Access and Out-of-Pocket Costs.
- Published in:
- Journal of Management Policy & Practice, 2024, v. 25, n. 3, p. 86, doi. 10.33423/jmpp.v25i3.7343
- By:
- Publication type:
- Article
14
Pharmacy Benefit Manager Market Concentration for Prescriptions Filled at US Retail Pharmacies.
- Published in:
- JAMA: Journal of the American Medical Association, 2024, v. 332, n. 15, p. 1298, doi. 10.1001/jama.2024.17332
- By:
- Publication type:
- Article
15
Pharmacy Middlemen Profit at Patients' Expense, Says FTC.
- Published in:
- JAMA: Journal of the American Medical Association, 2024, v. 332, n. 8, p. 611, doi. 10.1001/jama.2024.13776
- By:
- Publication type:
- Article
16
Costs and Essential Drug Access—The Case of Naloxone.
- Published in:
- 2024
- By:
- Publication type:
- Opinion
17
Federal Trade Commission Oversight of the Pharmaceutical Industry.
- Published in:
- 2024
- By:
- Publication type:
- Opinion
18
Pharmacy Benefit Managers.
- Published in:
- Journal of Financial Service Professionals, 2019, v. 73, n. 5, p. 35
- By:
- Publication type:
- Article
19
Cats at the Christening: Bundled Rebates, Doctrinal Blind Spots, and the Risks of Antitrust Under-Enforcement in the Biologic Pharmaceutical Market.
- Published in:
- University of Memphis Law Review, 2021, v. 51, n. 4, p. 917
- By:
- Publication type:
- Article
20
The Case of PBMs.
- Published in:
- Regulation, 2024, v. 47, n. 4, p. 31
- By:
- Publication type:
- Article
21
Introduction.
- Published in:
- Regulation, 2024, v. 47, n. 4, p. 28
- By:
- Publication type:
- Article
22
Eliminating Rebates in Medicare Part D Will Not Reduce Drug Prices.
- Published in:
- Regulation, 2020, v. 43, n. 3, p. 8
- By:
- Publication type:
- Article
23
THE "TROUBLES" WITH PHARMACY BENEFIT MANAGERS.
- Published in:
- Regulation, 2017, v. 40, n. 1, p. 14
- By:
- Publication type:
- Article
24
As Gridlock Grips Washington, State Legislatures Lead in Shaping Policy.
- Published in:
- Senior Care Pharmacist, 2025, v. 40, n. 3, p. 150, doi. 10.4140/TCP.n.2025.150
- By:
- Publication type:
- Article
25
The Recalibration of Power: Republicans Take Control of the Senate and Key Health Care Committees.
- Published in:
- Senior Care Pharmacist, 2025, v. 40, n. 2, p. 105, doi. 10.4140/TCP.n.2025.105
- By:
- Publication type:
- Article
26
Pharmacy Benefit Management Companies: Do They Create Value in the US Healthcare System?
- Published in:
- 2017
- By:
- Publication type:
- journal article
27
"What about Pharmacy Benefits Managers (PBMs)?".
- Published in:
- Neonatology Today, 2019, v. 14, n. 3, p. 44
- By:
- Publication type:
- Article
28
CAN HEALTH INSURERS BE LIABLE FOR FACILITATING THE OVERSUPPLY OF PRESCRIPTION OPIOIDS?
- Published in:
- Review of Litigation, 2022, v. 42, n. 1, p. 35
- By:
- Publication type:
- Article
29
PBM Competition in Pharmaceutical Supply Chain: Formulary Design and Drug Pricing.
- Published in:
- Manufacturing & Service Operations Management (M&SOM), 2015, v. 17, n. 4, p. 511, doi. 10.1287/msom.2015.0542
- By:
- Publication type:
- Article
30
Eyes on New Product Development.
- Published in:
- 2025
- By:
- Publication type:
- Editorial
31
Eyes on New Product Development.
- Published in:
- 2024
- By:
- Publication type:
- Editorial
32
Competition and price among brand-name drugs in the same class: A systematic review of the evidence.
- Published in:
- PLoS Medicine, 2019, v. 16, n. 7, p. 1, doi. 10.1371/journal.pmed.1002872
- By:
- Publication type:
- Article
33
Prescription Drug Advisory Boards and Drug Importation--At or Coming to a State Near You?
- Published in:
- Oncology Practice Management, 2024, v. 14, n. 5, p. 5
- By:
- Publication type:
- Article
34
Massive CAA Shake-up Looming for Health Benefits, Empowering Patients.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 10, p. 1
- By:
- Publication type:
- Article
35
Oncology Community Raising Concerns About Utilization Management, PBMs.
- Published in:
- Oncology Practice Management, 2018, v. 8, n. 10, p. 17
- By:
- Publication type:
- Article
36
What Does the Future Hold for PBMs? Implications for Oncology Practices.
- Published in:
- Oncology Practice Management, 2018, v. 8, n. 10, p. 1
- By:
- Publication type:
- Article
37
SENIOR LIFE INSURANCE IN THE REPUBLIC OF MACEDONIA - STATE AND PERSPECTIVES.
- Published in:
- Horizons Series A, 2014, v. 13, p. 377
- By:
- Publication type:
- Article
38
EXPRESS SCRIPTS, INC. V. DEL. STATE EMPL. BENEFITS COMM.
- Published in:
- Delaware Journal of Corporate Law, 2022, v. 46, n. 2, p. 343
- By:
- Publication type:
- Article
39
The Inflation Reduction Act: A Champion for United States Drug Pricing Reform.
- Published in:
- Hinckley Journal of Politics, 2024, v. 25, p. 21
- By:
- Publication type:
- Article
40
The CVS-Aetna Merger: Another Large Bet on the Changing U.S. Health Care Landscape.
- Published in:
- 2018
- By:
- Publication type:
- journal article
41
HOW MUCH WILL IT COST? THE "PRICE" OF PHARMACEUTICAL GAG CLAUSES AND WHY THEIR PROHIBITION MAY NOT EQUATE TO SAVINGS.
- Published in:
- Seton Hall Law Review, 2020, v. 50, n. 4, p. 1179
- By:
- Publication type:
- Article
42
PHARMACY DESERTS AND ANTITRUST LAW.
- Published in:
- Boston University Law Review, 2024, v. 104, n. 6, p. 1593
- By:
- Publication type:
- Article
43
CAN ANTITRUST LAW CURE THE PHARMACY DESERT PROBLEM IN AMERICA?
- Published in:
- Boston University Law Review, 2024, v. 104, n. 6, p. 1657
- By:
- Publication type:
- Article
44
THE BENEFIT IS IN THE DETAILS: HOW PHARMACY BENEFIT MANAGERS HAVE REAPED PROFITS FROM INSULIN’S INCREASING LIST PRICE AND REMAINED UNSCATHED, UNTIL NOW.
- Published in:
- Widener Law Review, 2023, v. 29, n. 1, p. 97
- By:
- Publication type:
- Article
45
Pharmacy Benefit Managers and Their Obligations During Serious Prescription Drug Shortages.
- Published in:
- Clinical Pharmacology & Therapeutics, 2013, v. 93, n. 2, p. 143, doi. 10.1038/clpt.2012.224
- By:
- Publication type:
- Article
46
PHARMACOECONOMICS: Evidence, Money and Drug Selection.
- Published in:
- Plans & Trusts, 2020, v. 38, n. 2, p. 14
- By:
- Publication type:
- Article
47
PBMs and Medication Nonadherence.
- Published in:
- Plans & Trusts, 2013, v. 31, n. 4, p. 8
- By:
- Publication type:
- Article
48
Using linked electronic medical record-pharmacy data to examine lupus medication adherence: A retrospective cohort study.
- Published in:
- Lupus, 2024, v. 33, n. 12, p. 1299, doi. 10.1177/09612033241280695
- By:
- Publication type:
- Article
49
The Effect of Any Willing Provider and Freedom of Choice Laws on Prescription Drug Expenditures.
- Published in:
- American Law & Economics Review, 2015, v. 17, n. 1, p. 192, doi. 10.1093/aler/ahu013
- By:
- Publication type:
- Article
50
A PUSH FOR MORE PBM COST TRANSPARENCY.
- Published in:
- Strategic Finance, 2015, v. 96, n. 9, p. 13
- By:
- Publication type:
- Article